Long‐term studies are needed to evaluate the magnitude and duration of seizure control and the possibility to reduce or withdraw ASMs in subjects with IDH‐mutant gliomas who respond to vorasidenib; in this regard, the rate of seizure control following standard radio‐ and chemotherapy will serve as a benchmark for the evaluation of the role of IDH inhibitors. The gene discussed is IDH1; the disease is glioma.